Thus, leukemic cells that express AF4-MLL produce an additional coactivator complex (Benedikt et al., 2011) that may push the balance toward RUNX1 functioning as a general activator, and this may have an impact on whether RUNX1 is a tumor suppressor or an oncogene in different cell types (Figure 7A). This evidence concerns the gene KMT2A and neoplasm.